Literature DB >> 18344718

A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis.

Paul Jensen1, Vera Bril.   

Abstract

OBJECTIVES: Immunomodulation with plasma exchange is effective in preparing patients for thymectomy. Newer forms of immunomodulation, such as intravenous immunomodulation, require evaluation in this clinical setting.
METHODS: We conducted a retrospective chart review to determine if plasma exchange and intravenous immunoglobulin had comparable effectiveness in the preoperative preparation of patients with myasthenia gravis. RESULTS AND
CONCLUSIONS: The results show that intravenous immunoglobulin may have comparable efficacy in the preoperative preparation of patients with myasthenia gravis and that this therapy is a reasonable alternative to plasma exchange in this clinical setting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344718     DOI: 10.1097/CND.0b013e3181660807

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


  11 in total

Review 1.  [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

2.  Intravenous immunoglobulin for preparing myasthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis.

Authors:  J Gamez
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 3.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

4.  Comparison of IVIg and PLEX in patients with myasthenia gravis.

Authors:  D Barth; M Nabavi Nouri; E Ng; P Nwe; V Bril
Journal:  Neurology       Date:  2011-05-11       Impact factor: 9.910

Review 5.  Intravenous immunoglobulin for myasthenia gravis.

Authors:  Philippe Gajdos; Sylvie Chevret; Klaus V Toyka
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

6.  Current and emerging treatments for the management of myasthenia gravis.

Authors:  Sivakumar Sathasivam
Journal:  Ther Clin Risk Manag       Date:  2011-07-22       Impact factor: 2.423

7.  Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis.

Authors:  Josep Gamez; María Salvadó; Francesc Carmona; Miriam de Nadal; Laura Romero; Daniel Ruiz; Alberto Jáuregui; Olga Martínez; Javier Pérez; Pilar Suñé; María Deu
Journal:  Ther Adv Neurol Disord       Date:  2019-07-17       Impact factor: 6.570

8.  Risk factors of myasthenia crisis after thymectomy among myasthenia gravis patients: A meta-analysis.

Authors:  Yingcai Geng; Hanlu Zhang; Yun Wang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

9.  Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis.

Authors:  Nader Salari; Behnaz Fatahi; Yalda Bartina; Mohsen Kazeminia; Reza Fatahian; Payam Mohammadi; Shamarina Shohaimi; Masoud Mohammadi
Journal:  J Transl Med       Date:  2021-12-20       Impact factor: 5.531

Review 10.  Plasma exchange for myasthenia gravis.

Authors:  P Gajdos; S Chevret; K Toyka
Journal:  Cochrane Database Syst Rev       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.